Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

  • STATUS
    Recruiting
  • days left to enroll
    9
  • participants needed
    1452
  • sponsor
    Gangnam Severance Hospital
Updated on 14 March 2021

Summary

"Prospective, open label, randomized, multicenter study

  • Patients treated with a new generation of Everolimus-eluting stents (Synergy). After PTCA, patients are randomized to a group of DAPT for one year or a group of P2Y12 monotherapy after 3 months of DAPT. After 12 months of PTCA, evaluate major cardiovascular events and major bleeding events
  • This study is to confirm after PTCA, DAPT for three months is not considered to be inferior to keeping DAPT for a year.

Details
Condition Coronary Artery Occlusive Disease
Treatment 1. P2Y12 inhibitor monotherapy after 3 months of DAPT
Clinical Study IdentifierNCT03447379
SponsorGangnam Severance Hospital
Last Modified on14 March 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note